Blood test triggers treatment to stop autoimmune Flare-Ups

NCT ID NCT07451847

Summary

This study aims to find a better way to prevent disease flare-ups in people with two rare autoimmune conditions (GPA and MPA). It will compare two approaches: giving a treatment called rituximab as soon as a specific blood marker rises, versus the current standard of just monitoring closely. The goal is to see if the early treatment approach is more effective at keeping patients in remission.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANCA ASSOCIATED VASCULITIS (AAV) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hôpital Cochin

    Paris, 75014, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.